Primary central nervous system non-Hodgkin's lymphoma (PCNSL): Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) study 86-72-52

Brian Patrick O'Neill, Chiao Hua Wang, Judith R. O'Fallon

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Purpose: We herein report updated survival and toxicity data on the entire cohort of 53 eligible patients treated on North Central Cancer Treatment Group (NCCTG) protocol 86-72-52, which is now closed. Methods and Materials: An initial report was published in this journal in 1995. No substantive changes in the conclusions of that report were identified in this analysis. Median survival was 9.6 months for the entire cohort; median survival for the 20 patients who completed the prescribed protocol treatment was 20.7 months. The hematologic and non-hematologic toxicity distributions are virtually the same as those reported in the original paper. Results: Results are given for the entire group and for subsets defined by age ≤ 60 versus > 60 years, and < 70 versus ≥ 70 years of age. Conclusions: No significant differences were observed in any of the outcome variables by age group. There was, however, a nonsignificant suggestion of poorer outcome in those who were > 60 years of age.

Original languageEnglish (US)
Pages (from-to)559-563
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume43
Issue number3
DOIs
StatePublished - Feb 1 1999

Fingerprint

central nervous system
Non-Hodgkin's Lymphoma
therapy
Central Nervous System
cancer
toxicity
Survival
Antineoplastic Protocols
Neoplasms
Clinical Protocols
set theory
Therapeutics

Keywords

  • Brain tumor
  • Clinical trial
  • Combined modility therapy
  • PCNSL

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

@article{3820ccfa421c436f88ac08a70cd8c7b1,
title = "Primary central nervous system non-Hodgkin's lymphoma (PCNSL): Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) study 86-72-52",
abstract = "Purpose: We herein report updated survival and toxicity data on the entire cohort of 53 eligible patients treated on North Central Cancer Treatment Group (NCCTG) protocol 86-72-52, which is now closed. Methods and Materials: An initial report was published in this journal in 1995. No substantive changes in the conclusions of that report were identified in this analysis. Median survival was 9.6 months for the entire cohort; median survival for the 20 patients who completed the prescribed protocol treatment was 20.7 months. The hematologic and non-hematologic toxicity distributions are virtually the same as those reported in the original paper. Results: Results are given for the entire group and for subsets defined by age ≤ 60 versus > 60 years, and < 70 versus ≥ 70 years of age. Conclusions: No significant differences were observed in any of the outcome variables by age group. There was, however, a nonsignificant suggestion of poorer outcome in those who were > 60 years of age.",
keywords = "Brain tumor, Clinical trial, Combined modility therapy, PCNSL",
author = "O'Neill, {Brian Patrick} and Wang, {Chiao Hua} and O'Fallon, {Judith R.}",
year = "1999",
month = "2",
day = "1",
doi = "10.1016/S0360-3016(98)00450-7",
language = "English (US)",
volume = "43",
pages = "559--563",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Primary central nervous system non-Hodgkin's lymphoma (PCNSL)

T2 - Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) study 86-72-52

AU - O'Neill, Brian Patrick

AU - Wang, Chiao Hua

AU - O'Fallon, Judith R.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Purpose: We herein report updated survival and toxicity data on the entire cohort of 53 eligible patients treated on North Central Cancer Treatment Group (NCCTG) protocol 86-72-52, which is now closed. Methods and Materials: An initial report was published in this journal in 1995. No substantive changes in the conclusions of that report were identified in this analysis. Median survival was 9.6 months for the entire cohort; median survival for the 20 patients who completed the prescribed protocol treatment was 20.7 months. The hematologic and non-hematologic toxicity distributions are virtually the same as those reported in the original paper. Results: Results are given for the entire group and for subsets defined by age ≤ 60 versus > 60 years, and < 70 versus ≥ 70 years of age. Conclusions: No significant differences were observed in any of the outcome variables by age group. There was, however, a nonsignificant suggestion of poorer outcome in those who were > 60 years of age.

AB - Purpose: We herein report updated survival and toxicity data on the entire cohort of 53 eligible patients treated on North Central Cancer Treatment Group (NCCTG) protocol 86-72-52, which is now closed. Methods and Materials: An initial report was published in this journal in 1995. No substantive changes in the conclusions of that report were identified in this analysis. Median survival was 9.6 months for the entire cohort; median survival for the 20 patients who completed the prescribed protocol treatment was 20.7 months. The hematologic and non-hematologic toxicity distributions are virtually the same as those reported in the original paper. Results: Results are given for the entire group and for subsets defined by age ≤ 60 versus > 60 years, and < 70 versus ≥ 70 years of age. Conclusions: No significant differences were observed in any of the outcome variables by age group. There was, however, a nonsignificant suggestion of poorer outcome in those who were > 60 years of age.

KW - Brain tumor

KW - Clinical trial

KW - Combined modility therapy

KW - PCNSL

UR - http://www.scopus.com/inward/record.url?scp=0033016902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033016902&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00450-7

DO - 10.1016/S0360-3016(98)00450-7

M3 - Article

C2 - 10078637

AN - SCOPUS:0033016902

VL - 43

SP - 559

EP - 563

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -